Autoinflammatory & rare systemic diseases
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS))
Methodological detailsEULAR/ACR recommendations, systematic literature review, Delphi methodology, multinational, multidisciplinary task force
- EULAR/ACR recommendations
- Systematic literature review
- Delphi methodology
- Multinational, multidisciplinary task force
Recommendations
As issued by the authors
Simultaneous need for prompt syndrome recognition
Systematic evaluation of underlying contributors
Early intervention targeting both hyperinflammation and likely contributors
Careful monitoring for progression/complications
Expert multidisciplinary assistance
Original publication
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →